Michael Gold to Patient Selection
This is a "connection" page, showing publications Michael Gold has written about Patient Selection.
Connection Strength
0.906
-
Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1236-44; discussion 1244-5.
Score: 0.331
-
Computer Modeling: The Future of Cardiac Resynchronization Therapy Patient Selection? Circ Arrhythm Electrophysiol. 2018 01; 11(1):e006104.
Score: 0.110
-
The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Heart Fail Clin. 2017 Jan; 13(1):209-223.
Score: 0.102
-
The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Card Electrophysiol Clin. 2015 Dec; 7(4):765-79.
Score: 0.095
-
Newer Indications for ICD and CRT. Cardiol Clin. 2014 May; 32(2):181-90.
Score: 0.084
-
Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: the Study of Atrial Fibrillation Reduction (SAFARI). Am Heart J. 2006 Aug; 152(2):231-6.
Score: 0.050
-
2018 ACC/AHA/HRS guideline on the?evaluation and management of patients with bradycardia and cardiac conduction delay: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. Heart Rhythm. 2019 09; 16(9):e227-e279.
Score: 0.029
-
2018 ACC/AHA/HRS guideline on the?evaluation and management of?patients with bradycardia and cardiac?conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2019 09; 16(9):e128-e226.
Score: 0.029
-
HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014 Jul 01; 130(1):94-125.
Score: 0.021
-
Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J. 2012 Jun; 163(6):954-962.e1.
Score: 0.019
-
Do Beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis. J Cardiovasc Electrophysiol. 2010 Sep; 21(9):1009-14.
Score: 0.017
-
Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Am Heart J. 2006 Feb; 151(2):288-94.
Score: 0.012
-
Toward a broader view of values in cost-effectiveness analysis of health. Hastings Cent Rep. 1999 May-Jun; 29(3):7-15.
Score: 0.008